Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Vahle, J. L.
Right arrow Articles by Nold, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vahle, J. L.
Right arrow Articles by Nold, J. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety

John L. Vahle

Lilly Research Laboratories, Greenfield, Indiana

Masahiko Sato

Lilly Research Laboratories, Greenfield, Indiana

Gerald G. Long

Lilly Research Laboratories, Greenfield, Indiana

Jamie K. Young

Lilly Research Laboratories, Greenfield, Indiana

Paul C. Francis

Lilly Research Laboratories, Greenfield, Indiana

Jeffery A. Engelhardt

Lilly Research Laboratories, Greenfield, Indiana

Michael S. Westmore

Lilly Research Laboratories, Greenfield, Indiana

Yanfei Linda Ma

Lilly Research Laboratories, Greenfield, Indiana

James B. Nold

Pathology Associates —A Charles River Company, Durham, North Carolina

Fischer 344 rats (60/sex/group) were given daily subcutaneou s injections of recombinant human parathyroi d hormone (PTH)(1-34) for 2 years at doses of 0, 5, 30, or 75 µg/kg. Treatment caused substantial increases in bone mass consistent with the known pharmacologic effects of once-daily administration. As determined by quantitative computed tomography (QCT) and histomorphometry, bone mass was markedly increased. Substantial new bone formation resulted in a large decrease in marrow space accompanied by altered bone architecture. Bone proliferative lesions were observed in all PTH(1-34)-treated groups. Osteosarcoma occurred in 3, 21, and 31 male rats and in 4, 12, and 23 female rats in the 5-, 30-, and 75- µg/kg treatment groups, respectively. Focal osteoblast hyperplasia, osteoma, and osteoblastoma were much less frequent. Although the specific cellular or molecular mechanisms responsible for the rat bone tumors have not been fully elucidated, the data suggest that these lesions resulted from the long duration of treatment and the exaggerated pharmacologic response of the rat skeleton to daily treatment with PTH(1-34). Important differences between the rat study and clinical use in adult humans suggest that the increased incidence of bone neoplasia in rats treated for 2 years is likely not predictive of an increased risk of bone cancer in skeletally mature adult humans being given PTH(1-34) for a limited period of time in the treatment of osteoporosis.

Key Words: Osteosarcoma • F344 rat • osteoma • osteoblastoma • carcinogenicity • QCT • bone mass • PTH.

Toxicologic Pathology, Vol. 30, No. 3, 312-321 (2002)
DOI: 10.1080/01926230252929882
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
W.-C. Lo, J.-F. Chiou, J. G. Gelovani, M.-L. Cheong, C.-M. Lee, H.-Y. Liu, C.-H. Wu, M.-F. Wang, C.-T. Lin, and W.-P. Deng
Transplantation of Embryonic Fibroblasts Treated with Platelet-Rich Plasma Induces Osteogenesis in SAMP8 Mice Monitored by Molecular Imaging
J. Nucl. Med., May 1, 2009; 50(5): 765 - 773.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
E. F. Nemeth
Anabolic Therapy for Osteoporosis: Calcilytics
IBMS BoneKEy, June 1, 2008; 5(6): 196 - 208.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
L. Gehrig, J. Lane, and M. I. O'Connor
Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. Stroup, M. P. Kane, and A. M. Abu-Baker
Teriparatide in the treatment of osteoporosis
Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 532 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. L. Vahle, M. Sato, and G. G. Long
Letter to the Editor
Toxicol Pathol, December 1, 2007; 35(7): 1045 - 1046.
[Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. Jolette, C. E. Wilker, S. Y. Smith, N. Doyle, J. F. Hardisty, A. J. Metcalfe, T. B. Marriott, J. Fox, and D. S. Wells
Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1-84 in a 2-Year Study in Fischer 344 Rats
Toxicol Pathol, December 1, 2006; 34(7): 929 - 940.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. L. Vahle, G. G. Long, G. Sandusky, M. Westmore, Y. L. Ma, and M. Sato
Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose
Toxicol Pathol, June 1, 2004; 32(4): 426 - 438.
[Abstract] [PDF]